Kenya BioVax Institute
Parastatal. Attached to a ministry, run by its own boardThe Kenya BioVax Institute is a state-owned company set up in 2021. It is building local capacity to make, package and sell vaccines and other health products. It also supports local drug makers.
- Established
- 2021
- Website
- biovax.go.ke
- info@biovax.go.ke
- Phone
- +254 775 751 639
- Office
- KWFT Centre, Upper Hill, Nairobi
- Postal address
- P.O. Box 40779-00100, Nairobi
- Social media
Leadership
Chairman of the Board
Charles GithinjiChairman, Board of Directors
Director General and Chief Executive Officer
Wesley RonohDirector General and Chief Executive Officer
General Manager, Commercial Services
Cecilia WanjalaGeneral Manager, Commercial Services
General Manager, Regulatory Affairs, Product Quality Assurance and Safety
Serah MuteruGeneral Manager, Regulatory Affairs, Product Quality Assurance and Safety
General Manager, Production
About KBI
Kenya BioVax Institute Limited is a state-owned company incorporated in 2021 to make, package and sell vaccines and other health products. A 2020 feasibility study looked at whether Kenya could make its own vaccines before Gavi support ends in 2029. The plan gained urgency during COVID-19 when poorer countries struggled to get vaccines. Its mandate also covers anti-cancer biosimilars, snake anti-venoms, insulin, infusions and rapid diagnostic kits. It is also meant to help local drug makers and to bring research products to market. It is preparing a vaccine fill-and-finish plant at Embakasi. It works with partners including France and the World Bank. Dr Wesley Ronoh is CEO. Its office is at KWFT Centre in Upper Hill, Nairobi.
Key figures
- Year incorporated
- 2021 2021 biovax.go.ke
- Planned plant site
- Embakasi, Nairobi 2026 biovax.go.ke
- CEO
- Dr Wesley Ronoh 2026 biovax.go.ke
Services
The institute supports local pharmaceutical firms to develop and produce quality products.
Technology transfer
It helps research institutions, colleges and universities turn research into products.

